What the session covered
The session examined how medtech regulatory professionals should read the current FDA landscape, with a focus on CDRH rather than leadership churn in the commissioner's office. Steve Silverman set out changes over 18 months, including QMSR, the RAPID pilot, guidance output, MDUFA commitments and slower authorisation times, and generative AI. Phil and David discussed the 2025 reduction in force, estimated at roughly 20 to 24 per cent of CDRH resources, its effect on review detail and morale, and early signs of hiring and stabilisation. Michelle covered QMSR misconceptions, the limits of ISO 13485 alignment, risk-based approach, culture of quality, management review, complaints and the medical device file. Jeff added small company concerns. The panel discussed inspection trends, risk as a top observation, 483 remediation across QSR and QMSR, MDUFA VI pre-submission changes including a proposed $2,000 fee, and practical use of pre-submissions and 513(g)s. The viewer takeaway is that CDRH is meeting many MDUFA timing goals but capacity and review substance remain under strain, so companies should document defensible regulatory positions, use informal FDA contact carefully, and prepare for QMSR and risk expectations.
Figures
Figures the speakers cited
Source: Bill Desjardins
Chapters
Jump to a moment
Times run from the start of the recording.
Take these with you
Six checks
Full recording
83:19Plays from YouTube when you press play. Cookie settings
How to cite this session
Sean, Silverman, S., Lott, M., Fillmore, D., Desjardins, B., Lips, J. (2026, September 22). FDA Ground Truth 2026 [Webinar]. MedTech Leading Voice, MedTech Leading Voice. medtechleadingvoice.com/watch/2026-09-22-fda-ground-truth-2026